-
Vorapaxar in atherosclerotic disease management.
The Annals of pharmacotherapy 20150501
-
Overview of the 2014 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee meeting regarding cangrelor.
The American journal of cardiology 20150415
-
Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics and pharmacodynamics of warfarin.
European journal of clinical pharmacology 20121101
-
Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial.
Lancet (London, England) 20121013
-
Platelet protease-activated receptor antagonism in cardiovascular medicine.
Coronary artery disease 20120901
-
Developing PAR1 antagonists: minding the endothelial gap.
Discovery medicine 20120601
-
Safety of the novel protease-activated receptor-1 antagonist vorapaxar in Japanese patients with a history of ischemic stroke.
Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association 20120501
-
Highlights of the American Heart Association Scientific Sessions 2011: a focus on ATLAS-TIMI 51, TRACER and PALLAS.
Expert review of cardiovascular therapy 20120301
-
Promises of PAR-1 inhibition in acute coronary syndrome.
Current cardiology reports 20120201
-
Thrombin-receptor antagonist vorapaxar in acute coronary syndromes.
The New England journal of medicine 20120105
-
Vorapaxar expands antiplatelet options. Which patients may benefit from thrombin receptor antagonism?
Hamostaseologie 20120101
-
Protease-activated receptor-1 inhibitors: a novel class of antiplatelet agents for the treatment of patients with acute coronary syndrome.
Advances in cardiology 20120101
-
PAR-1 inhibitors: a novel class of antiplatelet agents for the treatment of patients with atherothrombosis.
Handbook of experimental pharmacology 20120101
-
Vorapaxar: a novel protease-activated receptor-1 inhibitor.
Expert opinion on investigational drugs 20111001
-
Antiplatelet therapy: thrombin receptor antagonists.
British journal of clinical pharmacology 20111001
-
Oral antiplatelet therapy for atherothrombotic disease: current evidence and new directions.
American heart journal 20110301
-
Identification of human liver cytochrome P450 enzymes involved in the metabolism of SCH 530348 (Vorapaxar), a potent oral thrombin protease-activated receptor 1 antagonist.
Drug metabolism and disposition: the biological fate of chemicals 20110101
-
Inhibiting PAR-1 in the prevention and treatment of atherothrombotic events.
Expert opinion on investigational drugs 20101201
-
Discovery of a vorapaxar analog with increased aqueous solubility.
Bioorganic & medicinal chemistry letters 20101115
-
Challenges and promises of developing thrombin receptor antagonists.
Recent patents on cardiovascular drug discovery 20101101
-
Emerging oral antiplatelet therapies for acute coronary syndromes.
Hospital practice (1995) 20101101
-
Controversies and future perspectives of antiplatelet therapy in secondary stroke prevention.
Journal of cellular and molecular medicine 20101001
-
Thrombin receptor antagonists for the treatment of atherothrombosis: therapeutic potential of vorapaxar and E-5555.
Drugs 20101001
-
Mechanism of action and clinical development of platelet thrombin receptor antagonists.
Expert review of cardiovascular therapy 20100801
-
[Novel agents in antiplatelet therapy].
Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir 20100701
-
Molecular Medicine - CHI's 17th International Tri-Conference: Mastering Medicinal Chemistry - CHI's Seventh Annual Conference.
IDrugs : the investigational drugs journal 20100401
-
Safety and exploratory efficacy of the novel thrombin receptor (PAR-1) antagonist SCH530348 for non-ST-segment elevation acute coronary syndrome.
Journal of atherosclerosis and thrombosis 20100226
-
Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases.
British journal of pharmacology 20100201
-
Platelet thrombin receptor antagonism and atherothrombosis.
European heart journal 20100101
-
New antiplatelet agents: why they are needed.
European journal of internal medicine 20091201
-
Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?
Medical science monitor : international medical journal of experimental and clinical research 20091201
-
Differential effects of quercetin, apigenin and genistein on signalling pathways of protease-activated receptors PAR(1) and PAR(4) in platelets.
British journal of pharmacology 20091101
-
Improving antiplatelet therapy for atherothrombotic disease: preclinical results with SCH 530348, the first oral thrombin receptor antagonist selective for PAR-1.
Hamostaseologie 20091101
-
SCH-530348, a thrombin receptor (PAR-1) antagonist for the prevention and treatment of atherothrombosis.
Current opinion in investigational drugs (London, England : 2000) 20090901
-
SCH 530348: a novel oral thrombin receptor antagonist.
Future cardiology 20090901
-
New antiplatelet drugs: beyond aspirin and clopidogrel.
International journal of clinical practice 20090501
-
The ischaemia/bleeding balance in PCI.
Lancet (London, England) 20090314
-
Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study.
Lancet (London, England) 20090314
-
Current problems, new opportunities and future directions of anti-platelet therapy - increasing role of novel antiplatelet agents in cardiovascular diseases.
Recent patents on cardiovascular drug discovery 20090101
-
Update on antiplatelet therapy in acute coronary syndromes: what do new drugs bring into clinical practice?
American journal of cardiovascular drugs : drugs, devices, and other interventions 20090101
-
Advances in antiplatelet therapy for ACS and PCI.
Journal of interventional cardiology 20081201
-
Basic and translational research on proteinase-activated receptors: antagonism of the proteinase-activated receptor 1 for thrombin, a novel approach to antiplatelet therapy for atherothrombotic disease.
Journal of pharmacological sciences 20081201
-
Pharmacology of emerging novel platelet inhibitors.
American heart journal 20080801
-
Clinical overview of promising nonthienopyridine antiplatelet agents.
American heart journal 20080801
-
Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity.
Journal of medicinal chemistry 20080612